Variable phenotype of Alzheimer's disease with spastic paraparesis

Pedigrees with familial Alzheimer's disease (AD) show considerable phenotypic variability. Spastic paraparesis (SP), or progressive spasticity of the lower limbs is frequently hereditary and exists either as uncomplicated (paraparesis alone) or complicated (paraparesis and other neurological fe...

Full description

Saved in:
Bibliographic Details
Published inJournal of neurochemistry Vol. 104; no. 3; pp. 573 - 583
Main Authors Karlstrom, Helena, Brooks, William S, Kwok, John B.J, Broe, G. Anthony, Kril, Jillian J, McCann, Heather, Halliday, Glenda M, Schofield, Peter R
Format Journal Article
LanguageEnglish
Published Oxford, UK Oxford, UK : Blackwell Publishing Ltd 01.02.2008
Blackwell Publishing Ltd
Blackwell
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Pedigrees with familial Alzheimer's disease (AD) show considerable phenotypic variability. Spastic paraparesis (SP), or progressive spasticity of the lower limbs is frequently hereditary and exists either as uncomplicated (paraparesis alone) or complicated (paraparesis and other neurological features) disease subtypes. In some AD families, with presenilin-1 (PSEN1) mutations, affected individuals also have SP. These PSEN1 AD pedigrees frequently have a distinctive and variant neuropathology, namely large, non-cored plaques without neuritic dystrophy called cotton wool plaques (CWP). The PSEN1 AD mutations giving rise to CWP produce unusually high levels of the amyloid β peptide (Aβ) ending at position 42 or 43, and the main component of CWP is amino-terminally truncated forms of amyloid β peptide starting after the alternative β-secretase cleavage site at position 11. This suggests a molecular basis for the formation of CWP and an association with both SP and AD. The SP phenotype in some PSEN1 AD pedigrees also appears to be associated with a delayed onset of dementia compared with affected individuals who present with dementia only, suggesting the existence of a protective factor in some individuals with SP. Variations in neuropathology and neurological symptoms in PSEN1 AD raise the prospect that modifier genes may underlie this phenotypic heterogeneity.
Bibliography:http://dx.doi.org/10.1111/j.1471-4159.2007.05038.x
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0022-3042
1471-4159
1471-4159
DOI:10.1111/j.1471-4159.2007.05038.x